RxDoctor Payments Data

Srinivasulu Conjeevaram, MD

Family Medicine · Colchester, CTNPI 1780958058

Payments from drug & device makers

$695in general payments, 2019–2025

Across 25 payments — averaging $27.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biomerieux Inc$131
  • E.r. Squibb & Sons, L.L.C.$125
  • AstraZeneca$125
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$79
  • Takeda Pharmaceuticals U.S.A., Inc.$34
  • Actelion Pharmaceuticals US, Inc.$26
  • plus $174 from 9 others

What the payments were for

  • Food & beverage$695100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$695 in reported general payments places this provider in the 65th percentile of 588 family medicine providers in Connecticut.

See all family medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$356,272
Medicare patients
338
Services billed
1,948

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban107$61,249
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$15,798
JardianceEmpagliflozin16$14,726
Breo ElliptaFluticasone/Vilanterol21$8,737
XareltoRivaroxaban12$7,980
LinzessLinaclotide13$6,847
Rivastigmine27$5,235
Atorvastatin Calcium247$2,750
Metoprolol Succinate123$2,011
Levothyroxine Sodium182$1,798
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst98$1,627
Doxycycline Hyclate118$1,521
Memantine Hcl64$1,486
PaxlovidNirmatrelvir/Ritonavir21$1,429
Duloxetine Hcl39$1,258

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$15$62,679128 claims
GSKTrelegy Ellipta, Breo Ellipta$21$24,53541 claims
Boehringer IngelheimJardiance$23$14,72616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 588 family medicine providers in Connecticut.

Other family medicine in Colchester

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →